Merck & Co., Inc. (NYSE:MRK) Reaches New 12-Month High Following Analyst Upgrade

Key Points

• Merck shares reached a new 52-week high after Daiwa Securities upgraded the stock to “outperform” and set a $143 price target. The stock traded as high as $135.68, while analysts maintain a consensus “Moderate Buy” rating and $135.50 target.
• Merck reported quarterly revenue of $16.61 billion, above the $16.37 billion analyst estimate, with revenue up 5.1% year over year. Growth was supported by Keytruda, oncology products, new launches and Animal Health.
• Insiders have sold shares recently, including two executive vice presidents who together sold more than $4.3 million worth of stock; insiders sold 137,923 shares valued at $17.9 million over the past 90 days. Merck also declared a quarterly dividend of $0.85 per share, equivalent to a 2.5% annualized yield.

Merck & Co., Inc. (NYSE:MRK - Get Free Report)'s stock price reached a new 52-week high on Thursday after Daiwa Securities Group upgraded the stock from a neutral rating to an outperform rating. Daiwa Securities Group now has a $143.00 price target on the stock. Merck & Co., Inc. traded as high as $135.68 and last traded at $135.5750, with a volume of 8874817 shares trading hands. The stock had previously closed at $132.92.

A number of other research analysts have also weighed in on MRK. Bank of America lifted their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a "buy" rating in a research note on Tuesday, June 30th. Barclays increased their price objective on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 29th. Argus boosted their price objective on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a "buy" rating in a research report on Tuesday. Morgan Stanley upped their target price on shares of Merck & Co., Inc. from $112.00 to $113.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 9th. Finally, Wells Fargo & Company lifted their price target on Merck & Co., Inc. from $145.00 to $150.00 and gave the company an "overweight" rating in a research note on Wednesday, July 8th. Fifteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company's stock. Based on data from MarketBeat, Merck & Co., Inc. presently has an average rating of "Moderate Buy" and a consensus price target of $135.50.

Insider Buying and Selling at Merck & Co., Inc.

In related news, EVP Chirfi Guindo sold 15,000 shares of the firm's stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $131.00, for a total value of $1,965,000.00. Following the completion of the transaction, the executive vice president owned 46,613 shares of the company's stock, valued at approximately $6,106,303. This trade represents a 24.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP David R. Maraldo sold 18,706 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the sale, the executive vice president owned 18,212 shares in the company, valued at $2,344,248.64. The trade was a 50.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 137,923 shares of company stock valued at $17,908,943 over the last ninety days. 0.17% of the stock is currently owned by company insiders.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrades support the shares: Daiwa Securities raised Merck to “outperform” with a $143 price target, while Argus maintained a “buy” rating and lifted its target to $145. These actions reinforce the view that Merck’s recent momentum can continue. Merck analyst price target article
• Positive Sentiment: Keytruda and the core business remain strong: Merck’s second-quarter growth was driven primarily by Keytruda demand in early-stage and metastatic cancers, oncology products, new launches and Animal Health. Quarterly revenue of $16.61 billion exceeded the $16.37 billion consensus estimate, and revenue increased 5.1% year over year. Merck second-quarter earnings call article
• Positive Sentiment: Pipeline diversification is advancing: The FDA and European Medicines Agency accepted applications for broader ENFLONSIA use to prevent RSV in vulnerable young children. Expanded approval could create an additional growth avenue beyond oncology as Keytruda approaches eventual patent expiration. Merck ENFLONSIA RSV regulatory review article
• Neutral Sentiment: Earnings expectations are stable to slightly improved: Erste Group raised its FY2026 EPS estimate to $2.75 from $2.70, close to the roughly $2.77 consensus. Merck also declared its regular $0.85 quarterly dividend, or $3.40 annualized.
• Negative Sentiment: Keytruda concentration remains the main risk: Analysts caution that patent loss and increasing competition could eventually slow the drug’s sales growth, making the company’s pipeline and newer products increasingly important. Keytruda growth outlook article
• Negative Sentiment: Recent insider selling may temper sentiment: EVP Richard Deluca disclosed sales totaling more than 45,000 shares across transactions from August 10–12, while retaining a substantial position. The sales are not necessarily a fundamental signal, but could modestly weigh on investor confidence.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Kingdom Financial Group LLC. acquired a new position in Merck & Co., Inc. during the fourth quarter worth $25,000. Prosperity Bancshares Inc bought a new position in shares of Merck & Co., Inc. in the 4th quarter valued at about $26,000. Abound Financial LLC acquired a new position in shares of Merck & Co., Inc. during the 4th quarter worth about $26,000. Graney & King LLC increased its stake in shares of Merck & Co., Inc. by 400.0% during the 2nd quarter. Graney & King LLC now owns 250 shares of the company's stock worth $32,000 after purchasing an additional 200 shares during the last quarter. Finally, IFC & Insurance Marketing Inc. bought a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $31,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Performance

The company has a market capitalization of $334.49 billion, a P/E ratio of 108.46, a PEG ratio of 5.62 and a beta of 0.19. The stock's fifty day moving average price is $124.94 and its 200-day moving average price is $119.64. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.13. The business had revenue of $16.61 billion during the quarter, compared to analysts' expectations of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.Merck & Co., Inc.'s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter last year, the company posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, research analysts anticipate that Merck & Co., Inc. will post 2.77 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.5%. Merck & Co., Inc.'s payout ratio is presently 272.00%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source